Avastin uptake boosts Genentech
This article was originally published in Scrip
Executive Summary
Genentechreported a strong second quarter and raised its full-year guidance as its top two best-selling drugs, Avastin (bevacizumab) and Rituxan (rituximab), put in solid performances.